PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
- Resource Type
- article
- Source
- HemaSphere, Vol 7, p e3278692 (2023)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 - Language
- English
- ISSN
- 2572-9241